Australia markets open in 7 hours 22 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.21+0.49 (+5.62%)
As of 12:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.72
Open8.69
Bid9.20 x 1000
Ask9.22 x 1000
Day's range8.69 - 9.36
52-week range7.13 - 31.50
Volume379,857
Avg. volume939,565
Market cap712.937M
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-0.58
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.60
  • GlobeNewswire

    Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

    NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H

  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

    Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter end

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

    Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ETNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial r